Language

English

Publication Date

11-1-2023

Journal

EJHaem

DOI

10.1002/jha2.787

PMID

38024612

PMCID

PMC10660108

PubMedCentral® Posted Date

9-7-2023

PubMedCentral® Full Text Version

Post-print

Abstract

Lymphoma is one of the most common cancers in adolescents and young adults, but historically, this population has had lower clinical trial enrollment and improvements in overall survival as compared to other age populations. There are multiple challenges that are unique to this population that have affected drug development and clinical trial enrollment. Our panel of experts have identified barriers, and in this review, we discuss current methods to address these barriers as well as potential solutions moving forward.

Keywords

adolescent and young adults, clinical trials, lymphomas, new drug development

Published Open-Access

yes

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.